Cost-effectiveness of HIV screening of blood donations in Accra (Ghana).

Objectives: Areas with high HIV-incidence rates compared to the developed world may benefit from additional testing in blood banks and may show more favorable cost-effectiveness ratios. We evaluated the cost-effectiveness of adding p24 antigen, mini pool nucleic acid amplification testing (MPNAT), or individual donation NAT (ID-NAT) to the HIVantibody screening at the Korle Bu Teaching Hospital (Accra, Ghana), where currently only HIV-antibody screening is

[1]  Stuart Brody,et al.  Plausible and implausible parameters for mathematical modeling of nominal heterosexual HIV transmission. , 2007, Annals of epidemiology.

[2]  Elly Stolk,et al.  Towards a multi-criteria approach for priority setting: an application to Ghana. , 2006, Health economics.

[3]  E. Delaporte,et al.  Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study , 2006, AIDS.

[4]  M. Busch,et al.  Prevalence of HIV-1 in blood donations following implementation of a structured blood safety policy in South Africa. , 2006, JAMA.

[5]  R. Baltussen,et al.  Cost effectiveness analysis of strategies to combat HIV/AIDS in developing countries , 2005, BMJ : British Medical Journal.

[6]  Judith E. Brown,et al.  Predicting the failure of 3 by 5 , 2005, The Lancet.

[7]  S. Kleinman,et al.  Does prevalence of transfusion‐transmissible viral infection reflect corresponding incidence in United States blood donors? , 2005, Transfusion.

[8]  O. Laeyendecker,et al.  Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. , 2005, The Journal of infectious diseases.

[9]  J. Temple,et al.  Predonation screening of blood donors with rapid tests: implementation and efficacy of a novel approach to blood safety in resource‐poor settings , 2005, Transfusion.

[10]  E. Beck,et al.  The cost-effectiveness of highly active antiretroviral therapy, Canada 1991–2001 , 2004, AIDS.

[11]  R. Hayes,et al.  Transmission of HIV-1 infection in sub-Saharan Africa and effect of elimination of unsafe injections , 2004, The Lancet.

[12]  J. Wong,et al.  Cost‐effectiveness of nucleic acid test screening of volunteer blood donations for hepatitis B, hepatitis C and human immunodeficiency virus in the United States , 2004, Vox sanguinis.

[13]  J. AuBuchon,et al.  The cost‐effectiveness of NAT for HIV, HCV, and HBV in whole‐blood donations , 2003, Transfusion.

[14]  Modelling.  Improved methods and assumptions for estimation of the HIV/AIDS epidemic and its impact: Recommendations of the UNAIDS Reference Group on Estimates, Modelling and Projections. , 2002, AIDS.

[15]  R. Janssen,et al.  Estimated risk of HIV transmission by blood transfusion in Kenya , 2001, The Lancet.

[16]  R. Brookmeyer,et al.  Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda , 2001, The Lancet.

[17]  F. Sarkodie,et al.  Residual risk of transfusion in Ghana , 2001, British journal of haematology.

[18]  J. Acheampong,et al.  Screening for viral markers in volunteer and replacement blood donors in West Africa , 2001, Vox sanguinis.

[19]  R. Stott,et al.  The World Bank , 2008, Annals of tropical medicine and parasitology.

[20]  John Mullahy,et al.  Net Health Benefits: A New Framework for the Analysis of Uncertainty in Cost-Effectiveness Analysis , 1998 .

[21]  S. Kleinman,et al.  The incidence/window period model and its use to assess the risk of transfusion-transmitted human immunodeficiency virus and hepatitis C virus infection. , 1997, Transfusion medicine reviews.

[22]  E. Vamvakas,et al.  Epidemiology of blood transfusion , 1994, Transfusion.

[23]  K. Torpey,et al.  Ghana: preparing for the management of antiretroviral drugs. Findings and recommendations of the ARV assessment team. , 2003 .

[24]  Robert T. Chen,et al.  Model-based estimates of risks of disease transmission and economic costs of seven injection devices in sub-Saharan Africa. , 2002, Bulletin of the World Health Organization.

[25]  Andrew H Briggs,et al.  Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies. , 2002, Annual review of public health.

[26]  V. Lin.  Investing in Health Research and Development: Report of the Ad Hoc Committee on Health Research Relating to Future Intervention Options World Health Organization, Geneva, 1996 , 1997 .

[27]  S. Kleinman,et al.  The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. , 1996, The New England journal of medicine.

[28]  J. Murray,et al.  The Global Burden of Disease , 1996 .

[29]  P I Terasaki,et al.  Long-term survival. , 1988, Clinical transplants.